Corcept Therapeutics initiated with a Market Perform at SVB Securities

SVB Securities analyst Roanna Ruiz initiated coverage of Corcept Therapeutics with a Market Perform rating and $25 price target. While SVB Securities is constructive on the fundamentals of this company and thinks Corcept has achieved meaningful revenues with its one marketed rare-disease product Korlym in endogenous CS, the firm is ultimately waiting for a better entry point. the analyst tells investors in a research note.